A new brain imaging study has revealed that lysergic acid diethylamide (LSD) alters brain connectivity in ways that are notably different from methylenedioxyamphetamine (MDMA) and d-amphetamine.

A medicine based on MDMA – the active ingredient in recreational drug ecstasy – is on the cusp of FDA approval as a treatment for post-traumatic stress disorder (PTSD), according to the ...